对于患有慢性阻塞性肺病的GOLD组E患者,不同吸入疗法的治疗反应
Qing Song1,2,3,4, Ling Lin1,2,3,4, Tao Li1,2,3,4
1Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Journal of global health
|February 20, 2025
概括
对于GOLD组E的慢性阻塞性肺病 (COPD) 患者,治疗反应因分层而异. 像LABA/LAMA或LABA/LAMA/ICS这样的组合吸入器在FEV1%pred <50%和CAT ≥10.10的患者中显示出更好的结果.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
背景情况:
- 全球慢性阻塞性肺病倡议 (GOLD) 2023年指导方针更新了COPD评估,将C组和D组合为E组.
- 最初的吸入治疗建议也被修订,需要进一步评估治疗疗效.
研究的目的:
- 评估GOLD组E患者不同吸入疗法的有效性.
- 根据COPD评估测试 (CAT) 成绩和FEV1%预测,对治疗反应进行分层.
主要方法:
- 一项回顾性队列研究包括来自RealDTC研究 (2017-2023) 的3173名COPD患者.
- 患者被分配到GOLD组E,并根据FEV1%预测 (<50%对≥50%) 和CAT得分 (<10对≥10) 分层.
- 评估的疗法包括LAMA,LABA+ICS,LABA+LAMA和LABA+LAMA+ICS,并对恶化,住院和死亡率进行一年的随访.
主要成果:
- 对于FEV1%pred ≥50%和CAT <10.0的患者,治疗方法之间没有观察到显著的结果差异.
- 然而,LABA+LAMA或LABA+LAMA+ICS疗法与LAMA或LABA+ICS相比,在FEV1%pred <50%和CAT ≥10的患者中,导致恶化较少和恶化较频.
结论:
- 黄金E组患者需要进一步分层来确定最佳的初始吸入疗法.
- 基于详细的患者分层的个性化治疗方法可以改善GOLD组E COPD患者的结果.
相关概念视频
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
172
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
172
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
01:23Inhaled Medications
219
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
219
01:22Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K
01:17Drugs Used in Lower Respiratory Disorders: Overview
341
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
341